2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-156683
    CHK-336 2743436-86-2 98.50%
    CHK-336 (Example 1) is an orally active LDHA inhibitor (IC50<1 nM). CHK-336 inhibits lactate production in mouse hepatocytes. CHK-336 can be used in the study of hyperoxaluria.
    CHK-336
  • HY-156685
    EDI048 2767264-57-1 99.86%
    EDI048 is an orally active, gut-restricted parasiticidal agent. EDI048 specifically binds to the ATP-binding site of Cryptosporidium phosphatidylinositol 4-kinase (CpPI (4) K), blocks parasite membrane biogenesis, arrests the pathogen at the schizont stage, and thus irreversibly clears the infection. EDI048 is rapidly converted to an inactive carboxylic acid metabolite via hepatic first-pass metabolism, with extremely low systemic exposure, good safety profile, and no cardiotoxicity, genotoxicity or off-target effects. EDI048 is used in studies of intestinal cryptosporidiosis in children.
    EDI048
  • HY-158791
    Enpp-1-IN-21 2803505-78-2 99.07%
    Enpp-1-IN-21 (compound 4g) is an inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), with IC50 values for ENPP1 and ENPP3 at 0.45 and 0.19 μM, respectively.
    Enpp-1-IN-21
  • HY-163959
    PF-07853578 3036158-98-9 99.08%
    PF-07853578 is an orally active PNPLA3 modulator. PF-07853578 significantly reduces human PNPLA3-I148M protein levels and effectively decreases hepatic triglyceride content by reducing this mutant protein. PNPLA3 degrader-1 can be used in the research of liver cirrhosis and hepatocellular carcinoma.
    PF-07853578
  • HY-164605
    (6S)-CP-470711 300552-09-4 98.75%
    (6S)-CP-470711 (Compound 8) is an inhibitor for sorbitol dehydrogenase, that inhibits human and rat SDH with IC50 of 19 nM and 27 nM. (6S)-CP-470711 ameliorates the Streptozotocin (HY-13753)-induced diabetes in rats models.
    (6S)-CP-470711
  • HY-172157
    HDAC11-IN-2 2919766-97-3 99.52%
    HDAC11-IN-2 (compound B6) is a high selective Histone Deacetylase 11 (HDAC11) inhibitor. HDAC11-IN-2 inhibits HDAC11 and HDAC8 with IC50s of 51.1 ×10-3 μM and 5 μM, respectively. HDAC11-IN-2 inhibits denovolipogenesis (DNL) and promotes fatty acid oxidation, thus mitigating hepaticlipid accumulation and pathological symptoms in MASLD mice. HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at Thr172 through the inhibition of HDAC11, consequently modulating DNL and fatty acid oxidation in the liver.
    HDAC11-IN-2
  • HY-175222
    GlcNAc-MurNAc 41137-10-4
    GlcNAc-MurNAc, a disaccharide, is a TLR4 agonist with a Kd of 383 μM for murine TLR4. GlcNAc-MurNAc directly binds to TLR4 and activates its downstream NF-κB and IRF pathways. GlcNAc-MurNAc improves Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis in mice through a TLR4-dependent mechanism. GlcNAc-MurNAc can be used for the study of inflammatory bowel disease.
    GlcNAc-MurNAc
  • HY-21196A
    Potassium perfluorohexanesulfonate 3871-99-6 ≥98.0%
    Potassium perfluorohexanesulfonate is an orally active surfactant found in sera of the general population. Potassium perfluorohexanesulfonate induces adaptive hepatocellular hypertrophy, decreases serum cholesterol and increases alkaline phosphatase in male mice.
    Potassium perfluorohexanesulfonate
  • HY-A0181S
    Adenosine monophosphate-13C10,15N5 dilithium ≥99.0%
    Adenosine monophosphate-13C10,15N5(AMP-13C10,15N5) is the 13C-labeled and 15N-labeled Adenosine monophosphate (HY-A0181). Adenosine monophosphate is an adenosine A1 receptor agonist. Adenosine monophosphate has significant antiviral activity against HSV-1 and HSV-2. Adenosine monophosphate is a key cellular metabolite regulating energy homeostasis and signal transduction.
    Adenosine monophosphate-13C10,15N5 dilithium
  • HY-B0252R
    Hydrochlorothiazide (Standard) 58-93-5 99.55%
    Hydrochlorothiazide (Standard) is the analytical standard of Hydrochlorothiazide. This product is intended for research and analytical applications. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect.
    Hydrochlorothiazide (Standard)
  • HY-B0305A
    Roxatidine Acetate Hydrochloride 93793-83-0 99.57%
    Roxatidine Acetate Hydrochloride is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine Acetate Hydrochloride has antisecretory potency against gastric acid secretion. Roxatidine Acetate Hydrochloride can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine Acetate Hydrochloride has antitumor activity.
    Roxatidine Acetate Hydrochloride
  • HY-B0589C
    (3S,5S)-Atorvastatin 501121-34-2
    (3S,5S)-Atorvastatin is a inactive enantiomer of Atorvastatin. (3S,5S)-Atorvastatin can activate pregnane X receptor (PXR). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.
    (3S,5S)-Atorvastatin
  • HY-B0682A
    Mitiglinide calcium hydrate 207844-01-7 99.89%
    Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes.
    Mitiglinide calcium hydrate
  • HY-B0838S
    Imidacloprid-d4 1015855-75-0 98.86%
    Imidacloprid-d4 is the deuterium labeled Imidacloprid. Imidacloprid is an effective and widely used neonicotinoid pesticide to control pests of cereals, vegetables, tea and cotton.
    Imidacloprid-d4
  • HY-B0910A
    Pyrithioxin dihydrochloride 10049-83-9 98.0%
    Pyrithioxin (Pyritinol) dihydrochloride is the dihydrochloride salt of Pyrithioxin (HY-B0910). Pyrithioxin (Pyritinol) is an orally active neurodynamic compound. Pyrithioxin can promote the metabolism of glucose and amino acids, increase carotid blood flow and improve cerebral blood flow. Pyrithioxin exhibits anti-inflammation, anti-tumor and neuroprotective effect. Pyrithioxin can be used for the researches of cancer, inflammation, immunology, metabolic and neurological disease such as cerebral infarct, epilepsy, fibrosarcomas and rheumatoid polyarthritis.
    Pyrithioxin dihydrochloride
  • HY-B1613A
    Clebopride malate 57645-91-7 99.41%
    Clebopride malate is an orally active dopamine Receptor antagonist. Clebopride malate acts on dopamine D2 receptors and has antiemetic and prokinetic effects. Clebopride malate can be used in the study of functional gastrointestinal disorders.
    Clebopride malate
  • HY-B1827A
    D-Galacturonic acid 685-73-4 99.92%
    D-Galacturonic acid (D-galUA), as the main component of pectin, is abundantly present in plants. The carboxyl group of D-Galacturonic acid can bind to metal cations. D-Galacturonic acid plays an important role in the food industry, pharmaceutical field, and heavy metal removal, among other aspects.
    D-Galacturonic acid
  • HY-N10002
    Caffeoyltryptophan 109163-69-1 98.42%
    Caffeoyltryptophan is a competitive PTP1B inhibitor, with an IC50 of 16.99 μM. Caffeoyltryptophan can also inhibit α-glucosidase, linoleic acid peroxidation and haemolysis. Caffeoyltryptophan can be used for the research of type 2 diabetes.
    Caffeoyltryptophan
  • HY-N1902R
    4-Hydroxyphenylacetic acid (Standard) 156-38-7 99.24%
    4-Hydroxyphenylacetic acid (Standard) is the analytical standard of 4-Hydroxyphenylacetic acid. This product is intended for research and analytical applications. 4-hydroxyphenylacetic acid, a major microbiota-derived metabolite of polyphenols, is involved in the antioxidative action. 4-hydroxyphenylacetic acid induces expression of Nrf2. IC50 & Target:Nrf2 In Vivo: 4-Hydroxyphenylacetic acid (6, 12, or 25 mg/kg) increases Nrf2 translocation to the nucleus and enhances the activity of phase II and antioxidant enzymes. The protein levels of nuclear Nrf2 are increased by 170% and 230% in pre-treated 12 and 25 mg/kg 4-Hydroxyphenylacetic acid groups, respectively, compared with the control group.The 4-Hydroxyphenylacetic acid pretreatment at a final dose of 25 mg/kg markedly and selectively up-regulated the target genes of phase II enzymes and resulted in higher up-regulation than that of the control group by 270%, 400%, and 500% or UGT1A1, UGT1A9, and SULT2A1, respectively. 4-Hydroxyphenylacetic acid also suppresses the expression of CYP2E1.
    4-Hydroxyphenylacetic acid (Standard)
  • HY-N7091R
    Atrazine (Standard) 1912-24-9 99.21%
    Atrazine (Standard) is the analytical standard of Atrazine. This product is intended for research and analytical applications. Atrazine is principally used for control of certain annual broadleaf and grass weeds. Atrazine inhibits photophosphorylation but typically does not result in lethality or permanent cell damage in the short term.
    Atrazine (Standard)
Cat. No. Product Name / Synonyms Application Reactivity